We have had another successful quarter and are working hard to finish the year strong. We’re excited to announce that we’ve moved into our new headquarters on the Broadwest campus in the Vanderbilt/West End corridor of Nashville. This move allows us to continue collaborating with Vanderbilt University Medical Center and will accommodate our anticipated growth.

Highlights from the third quarter include:

NASHVILLE, Tenn., Nov. 1, 2022 – Cumberland Pharmaceuticals Inc.

Following our acquisition of oncology-supportive care medicine Sancuso^®

At Cumberland, we’re always seeking opportunities to maximize the potential of our existing brands, develop new ways to use our products, expand our roster of distinguished partners and acquire select new brands. We're pleased to share several notable developments on this front from the first quarter of 2022:

2021 was full of activity at Cumberland – and we’re especially proud to share several significant developments from a year that presented its share of challenges.

Although the COVID-19 pandemic continues to affect our lives and communities as we approach the end of 2021, we are optimistic as vaccination rates rise and case counts decline, and we remain fully operational while keeping our team safe and our facilities open.

Though the COVID-19 pandemic endures, we at Cumberland Pharmaceuticals remain hopeful as vaccination rates continue to rise. We are carefully monitoring the situation so that we can act quickly, if necessary, to keep our employees safe and our business strong.